- Home
- » Tags
- » Spartalizumab
Top View
- Biosimilar Antibodies & ELISA Kits
- Novartis Pipeline
- A61K9/51 (2006.01) — with International Search Report (Art
- Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Participants
- A Case Series of Melanoma Patients
- Q4 2020 Results Investor Presentation January 26, 2021 Disclaimer
- Development of Therapeutic Antibodies for the Treatment Of
- COMPANY NOTE Immutep Limited (IMM-AU) OUTPERFORM Unlocking the Value of LAG-3 in Autoimmunity Target Price AUD0.078 Current Price AUD0.030
- 2020 Medicines in Development ꟷ Cancer
- Adult Cancers
- Fc-Engineering for Modulated Effector Functions—Improving Antibodies
- Novel Immune Checkpoint Targets: Moving Beyond PD-1 and CTLA-4 Shuang Qin1, Linping Xu2, Ming Yi1, Shengnan Yu1, Kongming Wu1,2* and Suxia Luo2*
- Open-Label, Phase 1 Study of Nivolumab Combined with Nab-Paclitaxel Plus 2 Gemcitabine in Advanced Pancreatic Cancer
- Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: a Systematic Review and Meta-Analysis
- A View Into Upcoming Specialty & Traditional Drugs
- Novartis R&D
- Immutep Limited
- Spartalizumab in Addition to Dabrafenib and Trametinib for Unresectable Or Metastatic BRAF V600 Mutant Melanoma – First‐Line
- New Horizons with Immune Checkpoint Inhibitor Treatments in Autoimmunity, Transplant, and Cancer
- Identifying Gaps in Competitive Intelligence and Business Development Strategy: New Opportunities in the PD-1/PD-L1 Development Landscape
- Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
- WO 2018/223002 Al 06 December 2018 (06.12.2018) W ! P O PCT
- Immune-Checkpoint Inhibitors in B-Cell Lymphoma
- June 2020 Novartis Oncology Pipeline Update
- A View Into Upcoming Specialty & Traditional Drugs
- PDR001), an Anti–PD-1 Antibody, in Patients with Advanced Solid Tumors
- PDCO Minutes of the 24-27 July 2018 Meeting
- Biosimilar Monoclonalantibodies
- The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’S a Charm
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results from the Phase II KEYNOTE-158 Study
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine
- Targeting PD-1 Or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting David H
- Présentation Powerpoint
- Horizon Scanning Status Report, March 2021, Volume 3, Issue 1
- Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri